J&J's Q1'25 Earnings Call: Icotyde and JNJ-4804's immunology pathway in focus

Johnson & Johnson's (NYSE: JNJ) [Q1 2026 earnings call](https://seekingalpha.com/article/4890573-johnson-and-johnson-jnj-q1-2026-earnings-call-transcript), held April 14, revealed that the company's most consequential near-term pipeline signals are concentrated in immunology and oncology. During the earnings call hosted by CEO Joaquin Duato, J&J signaled that interleukin-23 (IL-23) receptor antagonist Icotyde (icotrokinra)’s expansion into inflammatory bowel disease (IBD) and the accelerated development of the co-antibody JNJ-4804 represent the key near-term risks and inflection points. ### Icotyde’s IBD expansion emerges as the central pipeline risk The most consequential pipeline discussion in the call centered on Icotyde, Johnson & Johnson’s IL-23 receptor-targeted oral peptide, approved in March 2026 for plaque psoriasis. While management positioned the drug as a potential first-line systemic therapy, the focus quickly shifted to its expansion into IBD, where Phase III programs in Crohn’s disease and ulcerative colitis are underway but remain unproven. Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine, explicitly conditioned the IBD opportunity on ongoing trials “panning out,” a level of caution not attached to the psoriasis indication. That distinction highlights the extent to which Icotyde’s long-term value proposition depends on outcomes that remain unresolved. Management has previously framed the asset as having the potential to become one of the company’s largest products, implying that failure in IBD would materially constrain that trajectory. The ICONIC ASCEND head-to-head trial against a TYK2 inhibitor, described as reading out imminently, represents the most immediate catalyst. John Reed, Executive Vice President of Innovative Medicine R&D, said the study is designed to validate Icotyde’s efficacy and safety profile, with the outcome also carrying weight in ongoing payer negotiations. Together with a Phase III psoriatic arthritis readout expected later in 2026, these events define the near-term clinical and commercial validation pathway for the drug. ### JNJ-4804 advances with limited public data A second key signal from the call was the development trajectory of JNJ-4804, a co-antibody combining guselkumab and golimumab for IBD. Reed said Phase III programs in both Crohn’s disease and ulcerative colitis are already underway, while Phase II data have yet to be publicly presented and are expected at a medical conference within the coming year. This sequencing—initiating pivotal studies ahead of public Phase II disclosure—signals strong internal confidence but also introduces execution risk. The Phase II readouts will be critical in defining patient selection and validating the co-antibody approach, leaving the current Phase III investment partially unsupported in the public domain. No analyst directly challenged this development strategy during the call. ### Analysts focus on Icotyde’s trajectory and JNJ-4804’s data gap Analyst questions during the call concentrated on two themes: Icotyde’s commercial and clinical trajectory, and the evidentiary basis for JNJ-4804. Multiple analysts pressed on Icotydes positioning across psoriasis and IBD, including how future revenue could split between the indications. Taubert declined to provide detailed projections, citing the dependence on IBD trial outcomes and the early stage of the launch. Separately, David Risinger of Leerink Partners asked about JNJ-4804’s role in treatment paradigms and the timing of its data disclosures. Reed confirmed that Phase II data would be presented within the year but did not specify timing, leaving the scientific foundation for the Phase III programs temporarily opaque. ### Near-term catalysts center on immunology readouts The call identified a narrow set of pipeline catalysts that will test Johnson & Johnson’s immunology strategy over the next 12 months. The ICONIC ASCEND trial readout is the most immediate event, with implications for both clinical positioning and payer access. This is followed by the Icotyde Phase III psoriatic arthritis data and the first public Phase II results for JNJ-4804 in IBD. Together, these readouts will determine whether the company’s strategy of combining a novel oral IL-23 approach with next-generation combination therapies can deliver the clinical differentiation required to sustain long-term growth. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/jj-icotyde-jnj-4804-ibd-jjs-and-signal-immunology)